Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

Belite Bio (NASDAQ: BLTE) announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, was filed with the SEC on March 31, 2026 and is available on the company website.

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE) announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, was filed with the SEC on March 31, 2026 and is available on the company website.

Shareholders may request a free hard copy of the annual report. The notice was issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).

Argus Mar 31 session

+6.88% close to close Open Argus

Details

News Market Reaction – BLTE

On Mar 31, the day this news came out, BLTE closed 6.88% above the previous close.

Data tracked by StockTitan Argus for the Mar 31 session.

Market Context

On Mar 31, the day this news came out, the stock closed 6.9% above the previous close. A strong posi...

Analysis

On Mar 31, the day this news came out, the stock closed 6.9% above the previous close. A strong positive reaction aligns with Belite Bio’s solid backdrop, including prior pivotal trial success and strengthened finances highlighted in earlier 2025 updates. Since this press release simply notifies investors that the audited Form 20-F for the year ended December 31, 2025 is available, any large move would more likely reflect investors revisiting those earlier clinical and financial details than the mechanics of this filing notice itself.

Key Figures

Fiscal year end: December 31, 2025

Fiscal year end

December 31, 2025

Audited consolidated financial statements referenced in Form 20-F

Historical Context

5 past events · Latest: Mar 02

5 events

1. Mar 02

   Conference participation

   24h Move

   -6.7%

   Announcement of participation in Leerink Global Healthcare Conference fireside chat.

2. Mar 02

   Earnings & update

   24h Move

   -6.7%

   Positive Phase 3 DRAGON topline data and 2025 prelim financials with major offering.

3. Feb 23

   Earnings call setup

   24h Move

   +4.6%

   Scheduling webcast to discuss preliminary Q4 and full-year 2025 results.

4. Jan 29

   Scientific meeting

   24h Move

   +2.0%

   Participation at APAO to present DRAGON topline data and case reports.

5. Jan 27

   Clinical milestone

   24h Move

   +3.0%

   Completion of enrollment in Phase 2/3 DRAGON II trial for Stargardt disease.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 20-f, securities and exchange commission, nasdaq listing rule 5250(d)(1)(c)

3 terms

form 20-f regulatory

"its annual report on Form 20-F, containing audited consolidated financial statements"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

securities and exchange commission regulatory

"as filed with the Securities and Exchange Commission on March 31, 2026"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

nasdaq listing rule 5250(d)(1)(c) regulatory

"This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C)."

NASDAQ Listing Rule 5250(d)(1)(c) is a regulatory requirement that forces a listed company to notify the exchange and the public when it has missed or will miss required SEC filings or other disclosure obligations that affect investors’ ability to evaluate the business. Think of it like a shop putting up a public notice when its financial records are late—the rule flags potential governance or reporting problems that can increase uncertainty, trading volatility, and the risk of regulatory action or delisting, so investors watch it as an early warning sign.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 31, 2026, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C).

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:

Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Belite Bio's Form 20-F filed March 31, 2026 include?

It includes the annual report and audited consolidated financial statements for the year ended December 31, 2025. According to Belite Bio, the Form 20-F was filed with the SEC on March 31, 2026 and the report is posted on the company's website for investor review.

How can BLTE shareholders obtain a hard copy of the 2025 annual report?

Shareholders may request a free physical hard copy of the annual report from the company. According to Belite Bio, requests can be submitted via the company's website, and the company will provide the hard copy at no charge to requesting shareholders.

Is the March 31, 2026 notice from Belite Bio related to a Nasdaq listing rule?

Yes — the company issued the notice pursuant to Nasdaq Listing Rule 5250(d)(1)(C) about annual report availability. According to Belite Bio, the Form 20-F filing on March 31, 2026 satisfies the Nasdaq notification requirement for posting the annual report.

Where can investors view or download Belite Bio's Form 20-F (BLTE)?

Investors can view and download the Form 20-F on Belite Bio's investor website at https://www.belitebio.com. According to Belite Bio, the filing was made with the SEC on March 31, 2026 and the annual report is available online for investors.

Does the 2025 Form 20-F for BLTE discuss the company's clinical-stage programs?

Yes — the annual report reflects the company's focus on clinical-stage therapeutics targeting degenerative retinal diseases. According to Belite Bio, the Form 20-F contains disclosures about its clinical-stage operations alongside the audited 2025 financial statements.